QCG
EPZM

Quadrant Capital Group’s Epizyme, Inc EPZM Stock Holding History

Quadrant Capital Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-547
Closed -$1K – 2773
2021
Q4 		$1K Buy
547
+500
+1,064% +$1.96K ﹤0.01% 2470
2021
Q3 		$0 Buy
+47
New +$285 ﹤0.01% 2719

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Quadrant Capital Group's EPZM Position: Q1 2022 in Review

Quadrant Capital Group sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 547 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in EPZM in Q3 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Quadrant Capital Group reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 547 Epizyme, Inc shares in Q1 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Epizyme, Inc in Q3 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Epizyme, Inc position peaked at $1K in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.